Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2025

Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

YTYi TangYCYan ChenTZTing Zeng

Discussion

Loading...

Member takes

Overview

Meta-analysis evaluates survival outcomes in endometrial cancer based on mismatch repair status, highlighting ICIs benefits.

Key Points

  • ICIs significantly improve survival for patients with mismatch repair-deficient (dMMR) endometrial cancer, while targeted therapies benefit those with proficient status.
  • In clinical trials, dMMR patients receiving Dostarlimab combined with carboplatin and paclitaxel showed the highest progression-free and overall survival rates.
  • Network meta-analysis incorporated randomized controlled trials, focusing on progression-free survival, overall survival, and adverse events among treatment groups.
  • These findings suggest tailored treatment strategies based on mismatch repair status can enhance outcomes in patients with endometrial cancer.

Cite This Study

Tang et al. (2025) studied this question.

synapsesocial.com/papers/68c235ccb210217d64771f36https://doi.org/10.1080/20565623.2025.2541517
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer2023 · 764 citations